Sunday, March 7, 2010

NEWER EYE MEDICATIONS: DIABETIC RETINOPATHY,EYE ALLERGY....

In DIABETES, a journal by the American Diabetes Association the role of Topical Administration of Nepafenac showed Inhibition of Diabetes-Induced Retinal Microvascular Disease and Underlying Abnormalities of Retinal Metabolism and Physiology.Professor Timothy S. Kern noted pharmacologic treatment of diabetic retinopathy via topical Nepafenac, an anti-inflammatory drug known to reach the retina when administered via eyedrops, on the development of early stages of diabetic retinopathy and on metabolic and physiologic abnormalities that contribute to the retinal disease.

Topical antihistamines & decongestants
Eye allergy drugs or Antihistamine eyedrops work by blocking histamine receptors in the conjunctiva. The histamine, therefore, is unable to attach to the conjunctiva and exert its effects. They are effective in relieving itching but have little impact on swelling or redness. They have advantages over antihistamine tablets; there is a faster onset of action and less drying of the eye. The new generation of topical antihistamines includes emedastine difumarate (Emadine) and levocabastine (Livostin). Patanol, a topical mast-cell stabilizer, is a safe, highly effective, long-acting treatment.). Side effects of few combination antihistamine-decongestant preparations are minimal, but the drops may become less effective if used for prolonged periods. They do have a potential for abuse and should not be used by people with narrow-angle glaucoma.

No comments: